



Docket No: ACY 33,377
Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Title of Application of: Thomas M. Metcalf III, et al.
Application No.: 09/674,368 Group Art No.:
Filed: April 29, 1999 Examiner:
For: VACCINES CONTAINING RECOMBINANT PILIN AGAINST
NEISSERIA GONORRHOEAE OR NEISSERIA MENINGITIDIS
Confirmation No.: 6981
Customer Number: 25291

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

RECEIVED

OCT 18 2005

TECH CENTER 1600/2000

INFORMATION DISCLOSURE STATEMENT

1. Preliminary Statements

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

CERTIFICATE OF MAILING 37 CFR §1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number ED451929201US addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

October 6, 2005
Date

Ann Peterson
Ann Peterson

10/11/2005 SFELEKE1 00000027 011425 09674368

01 FC:1806 180.00 DA

2. Identification of Time of Filing

This Information Disclosure Statement

- a. ☐ is filed within three months of the filing date of the application.
- b. ☒ is filed before the mailing date of a first Office Action on the merits.
- c. ☐ is filed before the mailing date of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.
- d. ☐ is filed after the period specified in 2(a), 2(b) or 2(c) above, but before the mailing date of a final action under 37 CFR 1.311. This statement includes a certification under 37 CFR 1.97(e) or the fee set forth in 37 CFR 1.17(p).
- e. ☐ is filed after the mailing date of a final action or Notice of Allowance but before payment of the issue fee. This statement includes (i) a certification under 37 CFR 1.97(e), and (ii) the fee set forth in 37 CFR 1.17(p).

3. ☐ Certification under 37 CFR 1.97(e) and 1.704(d)
The undersigned attorney certifies

- a. ☐ that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement, or
- b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the statement.
- c. ☐ certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign application patent office in a counterpart foreign application and was not received by any individual designated in 37 CFR 1.56(c) more than thirty (30) days prior to the filing of the statement.

4. ☒ Newly Cited Information
A legible copy of the patents, publications or other information cited on the attached form PTO 1449 is enclosed, except that no copy of a pending U.S. application is enclosed, and if this patent application was filed or entered the national stage after June 30, 2003, no copy of a U.S. patent or U.S. patent application publication is enclosed.

5. ☐ Previously Cited Information
No copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35 USC 120.
Prior application is Application Number _____, filed on _____ of _____ for _____

6. ☐ Concise Explanation
Documents cited above which are not in the English Language
- a. ☐ have been explained in the specification.
- b. ☐ have an abstract (or other concise explanation) in English enclosed or if readily available a translation into English of the document is enclosed.

Form PTO-1449 is enclosed in duplicate.

7. ☒ Fees
☒ Fee for filing under 37 CFR 1.97(c) or (d) Fee: \$180.00


Method of Payment of Fees:

Charge Deposit Account No. 01-1425 in the amount of \$180.00

A duplicate of this statement is enclosed.

Instructions as to Overpayment/Underpayment:

Credit any overpayment and charge any underpayment to Deposit Account No. 01-1425.



J. Darrell Fontenot
Attorney for Applicants
Reg. No. 46,705

Wyeth
Patent Law Department
Five Giralda Farms
Madison, NJ 07940
Tel. No. (845) 602-3144

SUBSTITUTE FOR Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known Application Number 09/674,368 Filing Date April 29, 1999 First Named Inventor Thomas N. Metcalf, III Group Art Unit Examiner Name Attorney Docket Number ACY33,377	
Sheet	1	of	2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If Known)			
	1.	4,443,431		Buchanan, T. M., et al.	04-17-1984	
	2.	4,702,911		McMichael, J. C.	10-27-1987	
	3.	5,098,998		Mekalanos, J. J., et al.	03-24-1992	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If Known)				
	4.	EP	0 202 260 B1		Mattick, J. S., et al.	06-03-1992		<input type="checkbox"/>
	5.	PCT	WO 92/13871		Normark, S., et al.	08-20-1992		<input type="checkbox"/>
	6.	PCT	WO 93/11791		Smith, A. W.	06-24-1993		<input type="checkbox"/>
	7.	PCT	WO 94/00153		Prieels, J., et al.	01-06-1994		<input type="checkbox"/>
	8.	PCT	WO 94/08013		So, M. Y.	04-14-1994		<input type="checkbox"/>
	9.	PCT	WO 96/31618		Sparling, P., et al.	10-10-1996		<input type="checkbox"/>

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	10.	ACHTMAN, M., et al.; The Journal of Infectious Diseases 165:53-68 (1992)	<input type="checkbox"/>
	11.	AHO, E. L., et al.; Infection and Immunity 65:7:2613-2620 (July 1997)	<input type="checkbox"/>
	12.	ALVES, A. M. B., et al.; American Society for Microbiology, Abstract E-79, Page 253 (1997)	<input type="checkbox"/>
	13.	BOSLEGO, J. W., et al.; Vaccine 9:154-162 (March 1991)	<input type="checkbox"/>
	14.	BUCHANAN, T. M., et al.; Bacterial Vaccines, Chapter 21, Pages 160-164 (1982)	
	15.	CARRICK, C. S., et al.; Gene 198:89-97 (October 1997)	
	16.	DAVIES, J. K., et al.; Fimbriae, Adhesion, Genetics, Biogenesis and Vaccines, Chapter 10, Pages 147-155 (1994)	<input type="checkbox"/>
	17.	EISENSTEIN, B. I. and KOOMEY, J. M.; Recombinant DNA Vaccines: Rationale and Strategies, Chapter 5, Pages 89-113 (1992)	<input type="checkbox"/>
	18.	ELLEMAN, T. C., et al.; Infection and Immunity 51:1:187-192 (January 1986)	<input type="checkbox"/>
	19.	EMERY, D. L., et al.; Australian Veterinary Journal 61:7:237-238 (July 1984)	<input type="checkbox"/>
	20.	FOREST, K. T. and TAINER, J. A.; Vaccines 97, Pages 167-173 (1997)	<input type="checkbox"/>
	21.	GUPTA, R. K., et al.; Vaccine 13:14:1263-1276 (October 1995)	
	22.	HECKELS, J. E.; Clinical Microbiology Reviews 2 (Suppl.), Pages S66-S73 (April 1989)	<input type="checkbox"/>
	23.	HOYNE, P. A., et al.; Journal of Bacteriology 174:22:7321-7327 (November 1992)	<input type="checkbox"/>
	24.	HULL, R. A., et al.; Infection and Immunity 33:3:933-938 (September 1981)	<input type="checkbox"/>
	25.	LEPPER, A. W. D.; Australian Veterinary Journal 65:10:310-316 (October 1988)	<input type="checkbox"/>
	26.	LEVINE, M. M., et al.; Fimbriae, Adhesion, Genetics, Biogenesis and Vaccines, Chapter 18, Pages 255-270 (1994)	<input type="checkbox"/>
	27.	MAKRIDES, S. C.; Microbiological Reviews 60:3:512-538 (September 1996)	
	28.	MARINARO, M., et al.; Annals New York Academy of Sciences, 795:361-365 (October 1996)	<input type="checkbox"/>
	29.	MEYER, T. F., et al.; Cell 30:45-52 (August 1982)	<input type="checkbox"/>
	30.	NASSIF, X., et al.; Gene 192:149-153 (June 1997)	
	31.	O'MEARA, T. J., et al.; Immunology and Cell Biology 71:473-488 (1993)	<input type="checkbox"/>
	32.	OLAFSON, R. W., et al.; Infection and Immunity 48:2:336-342 (May 1985)	<input type="checkbox"/>
	33.	PERRY, A. C. F., et al.; Gene 60:85-92 (1987)	
	34.	POTTS, W. J. and SAUNDERS, J. R.; Molecular Microbiology 2:5:647-653 (1988)	<input type="checkbox"/>
	35.	ROBINSON, E. N. Jr., et al.; Molecular Microbiology 3:1:57-64 (1989)	<input type="checkbox"/>
	36.	ROTHBARD, J. B., et al.; Proc. Natl. Acad. Sci. USA 82:915-919 (February 1985)	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		Complete if Known	
Application Number		09/674,368	
Filing Date		April 29, 1999	
First Named Inventor		Thomas N. Metcalf, III	
Group Art Unit			
Examiner Name			
Sheet	2	of	2
Attorney Docket Number		ACY33,377	

RECEIVED
 OCT 13 2005
 TECH CENTER 160012900

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	37.	ROTHBARD, J. B. and SCHOOLNIK; Adv. Exp. Med. Biol. 185:247-273 (1985)	<input type="checkbox"/>
	38.	SAUKKONEN, K. and LEINONEN, M.; Gonococci and Meningococci, Pages 815-820 (1986)	<input type="checkbox"/>
	39.	SCHOOLNIK, G. K., et al.; Journal of Experimental Medicine 159:1351-1370 (May 1984)	<input type="checkbox"/>
	40.	SEIFERT, H. S., et al.; Vaccine 6:107-109 (April 1988)	<input type="checkbox"/>
	41.	SEIFERT, H. S.; Molecular Microbiology 21:3:433-440 (1996)	<input type="checkbox"/>
	42.	SPARLING, P. F., et al.; Proc. Natl. Acad. Sci. USA 91:2456-2463 (March 1994)	<input type="checkbox"/>
	43.	STEPHENS, D. S.; Clinical Microbiology Reviews 2 (Suppl), Pages S104-S111 (April 1989)	<input type="checkbox"/>
	44.	STEWART, D. J., et al.; Australian Veterinary Journal 62:5:157-155 (May 1985)	<input type="checkbox"/>
	45.	STEWART, D. J., et al.; Veterinary Microbiology 27:283-293 (1991)	<input type="checkbox"/>
	46.	STROM, M. S. and LORY, S.; Annu. Rev. Microbiol. 47:565-596 (1993)	<input type="checkbox"/>
	47.	TENNENT, J. M. and MATTICK, J. S.; Fimbriae, Adhesion, Genetics, Biogenesis and Vaccines, Chapter 9, Pages 127-146 (1994)	<input type="checkbox"/>
	48.	TRAMONT, E. C.; Clinical Microbiology Reviews 2 (Suppl), Pages S74-S77 (April 1989)	<input type="checkbox"/>
	49.	TRAMONT, E. C., et al.; J. Clin. Invest. 68:881-888 (October 1981)	<input type="checkbox"/>
	50.	VIRJI, M., et al.; Molecular Microbiology 10:5:1013-1028 (1993)	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.